Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2386504 | 0.96 | CYP2D6 (0.30) | CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL3396062 | 0.96 | CYP2D6 (0.30) | CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL1308103 | 0.93 | CYP2D6 (0.31) | CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL4484382 | 0.93 | CYP2D6 (0.31) | CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL4630602 | 0.84 | HTR6 (0.40) | — | |
| SCHEMBL2461404 | 0.84 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL28260019 | 0.74 | — | — | |
| SCHEMBL9740934 | 0.71 | CTSL (0.35) | CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL9740930 | 0.71 | CTSL (0.35) | CYP2D6MEN1KMT2ALMNA | |
| SCHEMBL1307602 | 0.71 | CHRNB2 (0.34) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9233166-B2 | Supramolecular functionalization of graphitic nanoparticles for drug delivery | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-01-12 | — | — | US | disclosed |
| US-20140017322-A1 | SUPRAMOLECULAR FUNCTIONALIZATION OF GRAPHITIC NANOPARTICLES FOR DRUG DELIVERY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-01-16 | — | — | US | disclosed |
| US-8535726-B2 | Supramolecular functionalization of graphitic nanoparticles for drug delivery | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2013-09-17 | — | — | US | disclosed |
| EP-2332905-A1 | BCRP/ABCG3 Inhibitor | Kabushiki Kaisha Yakult Honsha (JP) | 2011-06-15 | — | — | EP | disclosed |
| EP-2182799-A1 | SUPRAMOLECULAR FUNCTIONALIZATION OF GRAPHITIC NANOPARTICLES FOR DRUG DELIVERY | The Board of Trustees of The Leland Stanford Junior University (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090087493-A1 | Supramolecular Functionalization of Graphitic Nanoparticles for Drug Delivery | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-04-02 | — | — | US | disclosed |
| WO-2009018092-A1 | SUPRAMOLECULAR FUNCTIONALIZATION OF GRAPHITIC NANOPARTICLES FOR DRUG DELIVERY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-02-05 | — | — | WO | disclosed |
| EP-0768895-B1 | CAMPTOTHECIN DRUG COMBINATIONS AND MEDICAMENTS WITH REDUCED SIDE EFFECTS | ARCH DEV CORP (US) | 2004-09-22 | — | — | EP | disclosed |
| US-5786344-A | ADMINISTERING WITH AGENT WHICH INCREASES ACTIVITY OF GLUCURONOSYLTRANSFERASE OR DECREASES ACTIVITY OF BILIARY TRANSPORT PROTEIN | ARCH DEVELOPMENT CORPORATION (US) | 1998-07-28 | — | — | US | disclosed |
| EP-0768895-A1 | CAMPTOTHECIN DRUG COMBINATIONS AND MEDICAMENTS WITH REDUCED SIDE EFFECTS | ARCH DEVELOPMENT CORPORATION (US) | 1997-04-23 | — | — | EP | disclosed |
| WO-1996001127-A1 | CAMPTOTHECIN DRUG COMBINATIONS AND MEDICAMENTS WITH REDUCED SIDE EFFECTS | ARCH DEVELOPMENT CORPORATION (US) | 1996-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090087493-A1 | Supramolecular Functionalization of Graphitic Nanoparticles for Drug Delivery | EPCAM, ILK, CD4 | CYP2D6 232/4885MEN1 3243/4885KMT2A 4130/4885 |
| US-20140017322-A1 | SUPRAMOLECULAR FUNCTIONALIZATION OF GRAPHITIC NANOPARTICLES FOR DRUG DELIVERY | ABCB1, CD63, EPCAM | CYP2D6 36/4885MEN1 2803/4885KMT2A 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.